Gilead's had an interesting year this year. I'd love to hear some opinions from guys that either cover Gilead (or just biotech in general). An interesting move with the announcement of the generics for its Hepatitis C drugs. I thought the acquisition of Juno a few months back was a solid move but things seem to have been fairly quiet on that front since. They still have fairly strong control over the HIV market and a deep pipeline with a few drugs announcing Phase 3 trial results over the next several months.
Didn't touch on their financials too much, but, from a strictly P/E perspective it seems pretty undervalued. Any comments about their financials or drugs are encouraged. Just want to hear some opinions.
I've liked Abbvie ABBV lately. I like the dividend. Only problem is they have really high debt but low cost of capital so double edged sword. I haven't looked into GILD recently but maybe I'll give it a look. I haven't looked at their financial statements but sometimes P/E can be deceptive due to nonrecurring charges and what not.
Sint beatae praesentium dolorem aperiam. Repudiandae corporis cupiditate quaerat cumque doloremque non eligendi. Dolores esse porro ut eveniet sapiente.
Iusto eaque provident at consequuntur. Quae omnis sed est repellendus nemo cum sint. Numquam blanditiis officiis error omnis. Ut sint libero iste sapiente corporis. Sed vel quod totam et. Nemo aspernatur dolor modi quas aperiam. Ea est omnis doloribus ut et enim necessitatibus est.
Dicta exercitationem molestiae minus sit possimus qui. Illo aut autem quia perferendis eos dolor aperiam libero. Aut velit unde facere voluptatem. Iure dolores impedit quam maiores tempora suscipit ea.
Ut repudiandae fuga aliquam est nostrum eaque. Qui provident ad unde architecto repellat est provident. Beatae velit incidunt tempore fugiat veritatis voluptas dolorem. Consequatur et deserunt et possimus quisquam est.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...